Pricing Log in Create free account
Saturday 17 October 2026 Export HAE’s income statement to Excel — free account

Haemonetics Corporation

HAE Healthcare Medical Devices

Haemonetics Corporation’s revenue for fiscal 2026 (year ended March 2026) was $1.3 billion, down 1.97% from fiscal 2025. In the quarter to June 2026, revenue grew 5.60%, EPS grew 2.86%, free cash flow grew 220.4% and total debt rose 27.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

118.28 3.01 −2.48%
Market cap
$5.5B
P/E
57.7×
Fwd P/E
18.0×
Dividend yield
—
F-score
6/9
Altman Z
2.21
Beneish M
−2.81
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.10
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy 1 — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 1.59%

Capital & Financial Ratios $m

Market Cap 5,520.00
Revenue 1,352.01
Net Income 96.29
Free Cash Flow 292.53
Net Debt 945.82
Current Ratio 3.08 (at or above 1.5: strong)
Debt/Equity 1.40
P/E ratio 57.70 (above 35: high)
Fwd P/E 18.00
P/S ratio 3.97
P/B ratio 6.41 (above 6: high)
Past 5Y EPS Growth 5.75%
This Y EPS Growth 7.12%
Next Y EPS Growth 9.50%
Next Y revenue growth 6.29%
Next 5Y EPS Growth 10.25%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 4.7×, against a ten-year median of 3.9×; over the ten years it ranged from 1.8× in 2016 to 7.4× in 2021.
P/E against its own 10 years 57.34%
10-year low 10-year high
P/S against its own 10 years 69.63%
10-year low 10-year high
P/B against its own 10 years 73.46%
10-year low 10-year high
EV/Sales against its own 10 years 73.94%
10-year low 10-year high
EV/FCF against its own 10 years 13.09%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2029 Powerpack
2028 Powerpack
2027 Powerpack
2026 Powerpack
2025 Powerpack
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2018 Powerpack
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2024 2025 2026 Q'26
Cash 179 307 245 223
Receivables 207 203 217 216
Inventory 317 365 306 307
Other — — — —
769 935 835 811
2024 2025 2026 Q'26
Payables 73 67 51 56
ST’ Debt — — — —
Other 136 148 158 164
300 578 283 263

Compound Annual Growth %

10y 5y 3y
Sales 3.91% 8.91% 4.51%
Cash Flow 9.18% 21.93% 2.40%
Earnings 0.00% 4.13% (5.53%)
Book Value 0.99% 1.71% (0.89%)

Revenue $m

Jun Sep Dec Mar Year
’26 339 — — — —
’26 321 327 339 346 1,334
’25 336 346 349 331 1,361
’24 311 318 336 343 1,309
’23 261 297 305 304 1,169
’22 229 240 260 265 993
’21 196 209 240 225 870
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Jun Sep Dec Mar Year
’26 52 — — — —
’26 17 111 94 71 293
’25 (27) 49 44 117 182
’24 19 99 (1) 64 182
’23 42 87 64 80 273
’22 (2) 43 62 68 172
’21 12 29 66 2 109
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Jun Sep Dec Mar Year
’26 45 — — — —
’26 14 106 88 54 262
’25 (13) 40 35 103 166
’24 12 91 (15) 58 145
’23 (3) 58 48 (20) 83
’22 (15) 23 36 34 78
’21 5 21 57 (9) 74
Fiscal quarters ending in the months shown.

EPS $

Jun Sep Dec Mar Year
’26 0.72 — — — —
’26 0.70 0.81 0.95 (0.44) 2.05
’25 0.74 0.66 0.74 1.17 3.31
’24 0.80 0.48 0.61 0.40 2.29
’23 0.38 0.64 0.64 0.57 2.24
’22 (0.09) 0.29 0.45 0.19 0.84
’21 0.21 0.94 0.62 (0.22) 1.55
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.7
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to March

Group Line 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 Trend 2027e 2028e 2029e
Price, $
Price, $ Low 36.44 60.51 80.24 63.41 49.26 43.50 72.26 70.25 47.32 51.00

Analyst estimates 2027–2029

Powerpack
High 58.99 117.56 140.36 126.74 142.11 86.58 95.26 97.97 87.32 123.77
People
People Employees 3,107 3,136 3,216 3,004 2,708 2,821 3,034 3,657 3,023 3,009
Revenue/emp, $m 0.29 0.29 0.30 0.33 0.32 0.35 0.39 0.36 0.45 0.44
Income, $m
Income, $m Revenue 886 904 968 988 870 993 1,169 1,309 1,361 1,334
Gross margin, % 42.71 45.57 43.15 49.02 45.70 50.90 52.63 52.83 55.04 59.04
EBT (27) 60 74 87 73 64 141 152 212 128
EBT margin, % (3.10) 6.60 7.61 8.82 8.38 6.41 12.10 11.60 15.58 9.60
Net income (26) 46 55 77 79 43 115 118 168 97
Depreciation 90 89 109 111 85 101 93 101 131 118
Per share, $
Per share, $ Revenue 17.20 17.13 18.78 19.50 17.17 19.46 23.01 25.82 27.04 28.28
Earnings (0.51) 0.85 1.07 1.51 1.57 0.84 2.24 2.32 3.33 2.05
Cash flow 3.10 4.18 3.09 3.12 2.15 3.37 5.38 3.58 3.61 6.22
Capex (1.42) (1.37) (2.25) (0.63) (0.69) (1.85) (3.74) (0.72) (0.32) (0.67)
Free cash flow 1.68 2.81 0.84 2.49 1.45 1.52 1.64 2.87 3.29 5.55
Book value 14.35 14.26 12.96 11.58 14.43 14.68 16.11 18.93 16.31 16.88
Shares, m 52 53 52 51 51 51 51 51 50 47
Valuation, ×
Valuation, × P/E 0.00 83.91 85.48 66.00 71.16 75.26 36.78 37.03 19.03 27.76
P/S 2.36 4.21 4.78 5.11 6.46 3.25 3.60 3.28 2.35 1.99
P/B 2.83 5.06 6.93 8.60 7.69 4.31 5.14 4.48 3.90 3.34
EV/Sales 2.49 4.08 4.94 5.28 7.04 3.55 4.00 3.76 2.80 2.72
EV/FCF 25.51 24.85 110.78 41.35 83.24 45.35 56.06 33.82 23.01 13.88
Cash, $m
Cash, $m Operating cash flow 160 220 159 158 109 172 273 182 182 293
Capex (73) (72) (116) (32) (35) (94) (190) (36) (16) (31)
Free cash flow 86 148 43 126 74 78 83 145 166 262
Balance, $m
Balance, $m Working capital 299 136 340 329 440 314 518 469 357 552
Total debt 254 59 322 306 691 559 754 798 921 1,220
Net debt 114 (121) 153 168 498 300 470 619 614 974
Shareholders’ equity 740 752 668 587 732 749 818 960 821 796
Returns, %
Returns, % ROA (2.05) 3.68 4.38 6.02 5.15 2.36 6.08 5.69 7.22 4.02
ROIC (1.42) 5.56 6.36 8.55 4.56 4.81 7.57 6.53 9.66 5.53
ROE (3.60) 6.11 7.75 12.20 12.05 5.86 14.72 13.22 18.83 12.03
Negative figures in brackets.

All 10 years →

Fiscal years to Mar 2026 · latest quarter Jun 2026

Charts ten years each

Haemonetics Corporation vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
BIO.B Bio-Rad Laboratories, Inc. $10.3B 43.7× — −0.09% (below 0%: shrinking) +19.02% (above 0%: growing) −6.06% (below 0%: shrinking) 53.12% 11.15% Compare
GKOS Glaukos Corporation $9.8B — (loss-making) — (loss-making) +49.54% (above 0%: growing) n/m +211.83% (above 0%: growing) 81.67% (9.30%) Compare
BIO Bio-Rad Laboratories, Inc. $9.8B 42.5× 35.4× −0.09% (below 0%: shrinking) +19.02% (above 0%: growing) −6.06% (below 0%: shrinking) 53.12% 11.15% Compare
PODD Insulet Corporation $9.6B 26.4× 24.7× +23.51% (above 0%: growing) +328.13% (above 0%: growing) −70.51% (below 0%: shrinking) 70.18% 16.18% Compare
BRKR Bruker Corporation $8.6B — (loss-making) 55.7× +5.15% (above 0%: growing) n/m +28.63% (above 0%: growing) 49.61% (7.79%) Compare
HAE Haemonetics Corporation $5.5B 57.7× 18.0× +5.60% (above 0%: growing) +2.86% (above 0%: growing) +220.38% (above 0%: growing) 59.76% 16.93%
LIVN LivaNova PLC $4.3B 22.5× 26.0× +10.80% (above 0%: growing) +296.00% (above 0%: growing) −26.66% (below 0%: shrinking) 70.07% 12.67% Compare
ITGR Integer Holdings Corporation $4.3B 34.3× 27.6× −2.60% (below 0%: shrinking) −34.91% (below 0%: shrinking) +48.81% (above 0%: growing) 24.34% 7.44% Compare
IRTC iRhythm Holdings, Inc. $3.6B — (loss-making) — (loss-making) +20.08% (above 0%: growing) n/m +116.98% (above 0%: growing) 72.80% (1.13%) Compare
Median of peers $9.1B 34.3× 27.6× +7.98% +19.02% +11.29% 61.60% 9.30%

All 149 Medical Devices stocks →

Haemonetics Corporation (HAE) key facts

  • Concern: Haemonetics Corporation’s revenue for fiscal 2026 (year ended March 2026) was $1.3 billion, down 1.97% from fiscal 2025.
  • Haemonetics Corporation (HAE) is a Medical Devices company in the Healthcare sector, listed on the New York Stock Exchange.
  • As of October 16, 2026, HAE traded at $118.28, a market capitalization of $5.5 billion.
  • Return on equity was 12.0% and debt-to-equity 1.40.
  • Its Piotroski F-score is 6 out of 9 and its Altman Z-score is 2.21 (grey zone) for fiscal 2026.

Source: company filings (standardised) and stockrow calculations.

Haemonetics Corporation (HAE) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/HAE · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com